<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="177633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782795</url>
  </required_header>
  <id_info>
    <org_study_id>CP-PENQEX-1R21AA017271</org_study_id>
    <secondary_id>R21AA017271</secondary_id>
    <secondary_id>1R21AA017271-01A1</secondary_id>
    <nct_id>NCT00782795</nct_id>
  </id_info>
  <brief_title>Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function &amp; Structure, Pain &amp; Life Quality</brief_title>
  <official_title>Phase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function &amp; Structure, Pain &amp; Life Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if study drug (Pioglitazone) treatment will
      improve pre-diabetes (insulin resistance) or ealy diabetes and improve clinical symptoms
      (pain) or laboratory evidence of chronic pancreatitis.

      The goal of the investigators is to gather information from this study to help gain
      understanding of a potential therapy for chronic pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pancreas is a digestive organ that secretes insulin (and other hormones) into the blood
      for regulating blood sugar (glucose) and digestive enzymes into the intestine for digesting
      and absorbing nutrients consumed in meals. Chronic pancreatitis is a progressive clinical
      disease of the pancreas, associated with swelling (inflammation), scarring (fibrosis) and
      loss of normal functioning tissue. Patients develop diabetes mellitus (elevated blood
      sugar), malabsorption of nutrients, weight loss and pain. Presently chronic pancreatitis is
      considered an irreversible condition because the mechanisms responsible for chronic
      pancreatitis are poorly understood and no therapy is proven. However, recent studies provide
      important clues that oral medications (Thiazolidinediones) used to treat diabetes mellitus
      might improve or reverse features of chronic pancreatitis, including elevated sugar or
      diabetes, reduced secretion of digestive enzymes, and pancreatic swelling and scarring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral glucose tolerance test.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity index for glycemia</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity index for glycemia</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance, sensitivity &amp; Beta-cell function</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreas ultrasound appearance</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, BMI, ER visits, Hospitalizations, Missed work</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic Function Test</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance, sensitivity, &amp; Beta-cell function</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, BMI, ER visits, Hospitalization, Missed Work</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, BMI, ER visits, Hospitalization, Missed Work</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, BMI, ER visits, Hospitalizations, Missed work</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, BMI, ER visits, Hospitalization, Missed work</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, BMI, ER visits, Hospitalization, Missed work</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <condition>Insulin Resistance</condition>
  <condition>Normal Stool Fat Levels</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 sugar pill (placebo) taken once daily for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_label>sugar pill (placebo)</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insulin resistance or mild diabetes mellitus

          -  Symptoms of abdominal pain

          -  Xray test showing damage to the pancreas

          -  Normal stool fat levels

        Exclusion Criteria:

          -  Mentally disabled patients

          -  Women who are planning pregnancy, pregnant or lactating/nursing

          -  Chronic pancreatitis is due to other specific conditions

               -  Autosomal dominant pancreatitis

               -  Classic cystic fibrosis with lung involvement

               -  Autoimmune pancreatitis

               -  Pancreatic cancer

               -  Biliary obstruction (non-pancreatic cause)

               -  Abdominal trauma

               -  Hypercalcemia

               -  Hypertriglyceridemia

          -  Surgical resection of the head of the pancreas

          -  Alcohol consumption within prior 2 months

          -  Specific medical conditions

               -  Gastric surgery

               -  Celiac sprue

               -  Crohns disease

               -  Heart failure

               -  Kidney failure

               -  Cirrhosis or liver disease

               -  Osteoporosis

               -  Blood clotting disorder

               -  Visual problems

               -  Low albumin

               -  Low BMI

          -  Specific medications *Diabetes drug treatment is allowed except for short-acting
             insulin, long-acting insule more than 15 units daily, pioglitazone, rosiglitazone,
             orlistat, acarbose, miglitol or voglibose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew DiMagno, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 6, 2016</lastchanged_date>
  <firstreceived_date>October 29, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Matthew DiMagno, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Chronic pancreatitis</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Decision will be made once the study results are produced.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
